Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top 10 Correlated ETFs
EHC
In the News

Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss
Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.

Encompass Health Encompasses Quality, Defensibility After Q2 FY22
Encompass Health posted Q2 FY22 earnings last week with downsides relative to consensus at the top and bottom line. Despite this, FCF remained buoyant and the company did recognize growth in most segments.

Encompass Health Corporation (EHC) CEO Mark Tarr on Q2 2022 Results - Earnings Call Transcript
Encompass Health Corporation (NYSE:EHC ) Q2 2022 Earnings Conference Call August 2, 2022 10:00 AM ET Company Participants Mark Miller - Chief IR Officer Mark Tarr - President and CEO Doug Coltharp - CFO Patrick Darby - General Counsel and Corporate Secretary Conference Call Participants Andrew Mok - UBS Joanna Gajuk - Bank of America Brian Tanquilut - Jefferies John Ransom - Raymond James Pito Chickering - Deutsche Bank Matthew Borsch - BMO Capital Markets Sarah James - Barclays Operator Good morning, everyone, and welcome to Encompass Health's Second Quarter 2022 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Miller, Encompass Health's Chief Investor Relations Officer.

Encompass Health (EHC) Q2 Earnings and Revenues Miss Estimates
Encompass Health (EHC) delivered earnings and revenue surprises of -8.25% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Encompass Health (EHC) to Report a Decline in Earnings: What to Look Out for
Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Encompass Health (EHC) to Build New Rehab Unit in Missouri
Encompass Health (EHC) and BJC HealthCare's new rehabilitation hospital is expected to come online in 2024.

Encompass Health (EHC) Opens EHR-Backed Hospital in Florida
Encompass Health (EHC) takes its U.S. inpatient rehabilitation hospital count to 150 with the opening of a hospital in Florida integrated with the sound EHR system of Oracle Cerner.

Encompass Health (EHC) Forms JV With NCH Healthcare in Naples
The NCH Healthcare System's board grants approval to invest in the joint venture with Encompass Health (EHC).

Four value-stock picks from a fund manager who steers clear of the energy sector
Jensen Investment Management follows a simple rule for initial screenings of stocks: Companies need to have achieved returns on equity (ROE) of at least 15% annually, for at least 10 consecutive years.

Encompass Health (EHC) Plans to Distribute Enhabit Shares
Every Encompass Health (EHC) shareholder will receive one Enhabit common share for every two EHC common shares held.
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 41.82 | 43.69 | 46.99 | 47.1 | 51.94 | |
Net income per share | 2.74 | 2.99 | 3.66 | 2.88 | 4.18 | |
Operating cash flow per share | 7.01 | 7.79 | 6.48 | 7.15 | 7.26 | |
Free cash flow per share | 4.4 | 5.02 | 2.36 | 3.01 | 1.67 | |
Cash per share | 0.58 | 0.71 | 0.97 | 2.27 | 0.56 | |
Book value per share | 12.61 | 13.04 | 13.8 | 16.11 | 19.38 | |
Tangible book value per share | -10.15 | -10.08 | -11.11 | -7.91 | -4.53 | |
Share holders equity per share | 12.61 | 13.04 | 13.8 | 16.11 | 19.38 | |
Interest debt per share | 29.16 | 27.19 | 33.29 | 37.8 | 37.55 | |
Market cap | 3.97B | 5.19B | 6.02B | 6.31B | 4.87B | |
Enterprise value | 6.5B | 7.64B | 9.03B | 9.63B | 8.35B | |
P/E ratio | 15.5 | 17.77 | 16.79 | 22.19 | 11.81 | |
Price to sales ratio | 1.01 | 1.21 | 1.31 | 1.36 | 0.95 | |
POCF ratio | 6.05 | 6.81 | 9.48 | 8.95 | 6.8 | |
PFCF ratio | 9.64 | 10.56 | 26.05 | 21.27 | 29.57 | |
P/B Ratio | 3.36 | 4.07 | 4.45 | 3.97 | 2.55 | |
PTB ratio | 3.36 | 4.07 | 4.45 | 3.97 | 2.55 | |
EV to sales | 1.66 | 1.79 | 1.96 | 2.07 | 1.63 | |
Enterprise value over EBITDA | 8.6 | 10.08 | 10.59 | 11.81 | 8.58 | |
EV to operating cash flow | 9.88 | 10.02 | 14.21 | 13.66 | 11.67 | |
EV to free cash flow | 15.76 | 15.53 | 39.06 | 32.47 | 50.74 | |
Earnings yield | 0.06 | 0.06 | 0.06 | 0.05 | 0.08 | |
Free cash flow yield | 0.1 | 0.09 | 0.04 | 0.05 | 0.03 | |
Debt to equity | 2.15 | 1.94 | 2.24 | 2.18 | 1.81 | |
Debt to assets | 0.71 | 0.7 | 0.72 | 0.69 | 0.65 | |
Net debt to EBITDA | 3.34 | 3.23 | 3.53 | 4.07 | 3.58 | |
Current ratio | 1.36 | 0.98 | 1.05 | 1.32 | 1.23 | |
Interest coverage | 4.21 | 4.63 | 4.34 | 3.52 | 4.9 | |
Income quality | 2.56 | 2.61 | 1.77 | 2.48 | 1.74 | |
Dividend Yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Payout ratio | 0.36 | 0.34 | 0.3 | 0.39 | 0.27 | |
Sales general and administrative to revenue | 0.61 | 0.62 | 0.63 | 0.63 | 0.62 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.49 | 0.49 | 0.46 | 0.43 | 0.41 | |
Capex to operating cash flow | -0.37 | -0.35 | -0.64 | -0.58 | -0.77 | |
Capex to revenue | -0.06 | -0.06 | -0.09 | -0.09 | -0.11 | |
Capex to depreciation | -1.33 | -1.35 | -1.85 | -1.68 | -2.15 | |
Stock based compensation to revenue | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | |
Graham number | 27.86 | 29.6 | 33.71 | 32.32 | 42.7 | |
ROIC | 0.15 | 0.15 | 0.13 | 0.11 | 0.13 | |
Return on tangible assets | 0.1 | 0.11 | 0.11 | 0.08 | 0.1 | |
Graham Net | -32.66 | -32.67 | -39.93 | -38.77 | -39.56 | |
Working capital | 184.7M | -10.4M | 34.8M | 231.3M | 172.6M | |
Tangible asset value | -951.1M | -987.2M | -1.09B | -780M | -446.2M | |
Net current asset value | -2.77B | -2.96B | -3.63B | -3.53B | -3.54B | |
Invested capital | 2.18 | 1.97 | 2.29 | 2.23 | 1.85 | |
Average receivables | 522.45M | 520.25M | 539.45M | 572.8M | 626.55M | |
Average payables | 96.7M | 102.5M | 104.8M | 115M | 126.3M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 43.97 | 39.91 | 40.11 | 45.02 | 48.48 | |
Days payables outstanding | 191.67 | 206.99 | 205.65 | 209.35 | 239.96 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 8.3 | 9.15 | 9.1 | 8.11 | 7.53 | |
Payables turnover | 1.9 | 1.76 | 1.77 | 1.74 | 1.52 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.22 | 0.23 | 0.27 | 0.18 | 0.22 | |
Capex per share | -2.61 | -2.76 | -4.12 | -4.14 | -5.59 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 13.01 | 12.98 | 13.32 | 13.44 | 13.41 | |
Net income per share | 1.14 | 1.01 | 0.93 | 0.88 | 0.49 | |
Operating cash flow per share | 2.58 | 1.79 | 1.25 | 2.21 | 2.47 | |
Free cash flow per share | 1.33 | 0.52 | -0.79 | 1.05 | 1.26 | |
Cash per share | 0.74 | 0.96 | 0.55 | 0.95 | 1.88 | |
Book value per share | 17.8 | 18.61 | 19.31 | 19.89 | 20.19 | |
Tangible book value per share | -6.45 | -5.54 | -4.51 | -3.79 | -3.13 | |
Share holders equity per share | 17.8 | 18.61 | 19.31 | 19.89 | 20.19 | |
Interest debt per share | 35.04 | 35.32 | 36.14 | 35.79 | 36.21 | |
Market cap | 6.15B | 5.91B | 5.14B | 5.61B | 4.42B | |
Enterprise value | 9.5B | 9.27B | 8.62B | 9.03B | 7.77B | |
P/E ratio | 13.56 | 14.78 | 14.03 | 16.03 | 22.71 | |
Price to sales ratio | 4.77 | 4.6 | 3.9 | 4.21 | 3.32 | |
POCF ratio | 24.02 | 33.28 | 41.52 | 25.64 | 18.08 | |
PFCF ratio | 46.56 | 115.88 | -65.81 | 54.12 | 35.42 | |
P/B Ratio | 3.49 | 3.21 | 2.69 | 2.84 | 2.21 | |
PTB ratio | 3.49 | 3.21 | 2.69 | 2.84 | 2.21 | |
EV to sales | 7.38 | 7.22 | 6.54 | 6.77 | 5.84 | |
Enterprise value over EBITDA | 36.82 | 38.81 | 37.66 | 40.22 | 34.43 | |
EV to operating cash flow | 37.12 | 52.21 | 69.65 | 41.24 | 31.76 | |
EV to free cash flow | 71.97 | 181.81 | -110.41 | 87.06 | 62.2 | |
Earnings yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Free cash flow yield | 0.02 | 0.01 | -0.02 | 0.02 | 0.03 | |
Debt to equity | 1.88 | 1.82 | 1.81 | 1.74 | 1.72 | |
Debt to assets | 0.67 | 0.66 | 0.65 | 0.64 | 0.64 | |
Net debt to EBITDA | 13 | 14.07 | 15.21 | 15.22 | 14.83 | |
Current ratio | 1.07 | 1.15 | 1.23 | 1.26 | 1.24 | |
Interest coverage | 5.24 | 5 | 4.5 | 4.64 | 2.67 | |
Income quality | 2.26 | 1.78 | 1.35 | 2.5 | 5.02 | |
Dividend Yield | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.25 | 0.28 | 0.3 | 0.33 | 0.57 | |
Sales general and administrative to revenue | 0.61 | 0.62 | 0.64 | 0.63 | 0.64 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.43 | 0.42 | 0.41 | 0.41 | 0.4 | |
Capex to operating cash flow | -0.48 | -0.71 | -1.63 | -0.53 | -0.49 | |
Capex to revenue | -0.1 | -0.1 | -0.15 | -0.09 | -0.09 | |
Capex to depreciation | -1.95 | -1.95 | -3.07 | -1.74 | -1.74 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 21.41 | 20.57 | 20.05 | 19.87 | 14.93 | |
ROIC | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | |
Return on tangible assets | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | |
Graham Net | -38.99 | -38.94 | -39.4 | -38.77 | -38.88 | |
Working capital | 54.8M | 115.9M | 172.6M | 195.2M | 197M | |
Tangible asset value | -638.8M | -548.4M | -446.2M | -375.5M | -310.3M | |
Net current asset value | -3.54B | -3.52B | -3.54B | -3.5B | -3.51B | |
Invested capital | 1.95 | 1.88 | 1.85 | 1.78 | 1.76 | |
Average receivables | 655.5M | 660.65M | 681.9M | 683.5M | 671.1M | |
Average payables | 146.2M | 148.35M | 142.45M | 147.3M | 142.8M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 43.86 | 44.68 | 46.43 | 46.13 | 44.56 | |
Days payables outstanding | 261.18 | 252.74 | 228.49 | 236.31 | 235.74 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 2.05 | 2.01 | 1.94 | 1.95 | 2.02 | |
Payables turnover | 0.34 | 0.36 | 0.39 | 0.38 | 0.38 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.06 | 0.05 | 0.05 | 0.04 | 0.02 | |
Capex per share | -1.25 | -1.28 | -2.04 | -1.16 | -1.21 |